This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Ceapro 대차 대조표 상태

재무 상태 기준 확인 6/6

Ceapro 의 총 주주 지분은 CA$27.9M 이고 총 부채는 CA$0.0, 이는 부채 대 자기자본 비율을 0% 로 가져옵니다. 총자산과 총부채는 각각 CA$31.4M 및 CA$3.6M 입니다.

주요 정보

부채 비율

CA$0

부채

이자 보상 비율	n/a
현금	CA$8.84m
주식	CA$27.86m
총 부채	CA$3.59m
총 자산	CA$31.45m

최근 재무 상태 업데이트

Recent updates

Ceapro Inc. (CVE:CZO) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?

Nov 28

재무 상태 분석

단기부채: CZO 의 단기 자산 ( CA$14.8M )이 단기 부채( CA$1.7M ).

장기 부채: CZO 의 단기 자산( CA$14.8M )이 장기 부채( CA$1.9M ).

부채 대 자본 내역 및 분석

부채 수준: CZO 부채가 없습니다.

부채 감소: CZO 는) 부채 대 자기자본 비율이 2.7% 였던 5년 전과 비교하여 부채가 없습니다.

부채 범위: CZO 은 부채가 없으므로 영업현금흐름으로 충당할 필요가 없습니다.

이자 보장: CZO 에는 부채가 없으므로 이자 지불에 대한 보장은 문제가 되지 않습니다.

This company is no longer active

Ceapro 대차 대조표 상태

재무 상태 기준 확인 6/6

주요 정보

최근 재무 상태 업데이트

Ceapro Inc. Ordinary Shares to Be Deleted from OTC Equity

Recent updates

Ceapro Inc. Ordinary Shares to Be Deleted from OTC Equity

Aeterna Zentaris Inc. (TSX:AEZS) completed the acquisition of Ceapro Inc. (TSX:AEZS) in a merger of equals transaction.

Aeterna Zentaris Inc. (TSX:AEZS) entered into a definitive agreement to acquire Ceapro Inc. (TSXV:CZO) for CAD 21.4 million in a merger of equals.

Third quarter 2023 earnings released: CA$0.013 loss per share (vs CA$0.011 profit in 3Q 2022)

Ceapro Inc. Initiates Phase 1-2A Study Assessing Its Product Avenanthramides for Potential Applications in Inflammation Based Diseases

Ceapro Inc. Initiates Phase 1-2A Study Assessing Its Product Avenanthramides for Potential Applications in Inflammation Based Diseases

Second quarter 2023 earnings released: CA$0.015 loss per share (vs CA$0.021 profit in 2Q 2022)

The Returns At Ceapro (CVE:CZO) Aren't Growing

Ceapro Inc. Announces Resignation of Glenn Rourke as A Director

First quarter 2023 earnings released: CA$0.005 loss per share (vs CA$0.026 profit in 1Q 2022)

Ceapro Inc. Presents Encouraging Results from Research Collaboration Study with McMaster University Evaluating PGX-Processed Yeast Beta Glucan for Interstitial Lung Diseases

Full year 2022 earnings released: EPS: CA$0.056 (vs CA$0.037 in FY 2021)

Ceapro Inc. Receives Approval from Health Canada to Commence Phase 1/2A Human Clinical Trial Assessing Avenanthramide Tablets

Third quarter 2022 earnings released: EPS: CA$0.011 (vs CA$0.011 in 3Q 2021)

Ceapro Inc. Launches Next Phase of Scale Up for Disruptive PGX Technology to Pursue Product Development for Nutraceutical and Pharmaceutical Markets

Returns At Ceapro (CVE:CZO) Are On The Way Up

Ceapro Inc. Announces Positive Data from Bioavailability Studies Evaluating CoQ10 Formulations Impregnated with PGX-Processed Carriers

Second quarter 2022 earnings released: EPS: CA$0.021 (vs CA$0.009 in 2Q 2021)

Ceapro Inc. Appoints Sigrun Watson as Chief Revenue Officer

Ceapro's (CVE:CZO) Returns Have Hit A Wall

Ceapro Inc. Appoints Ronnie Miller as Chairman of the Board and Genevieve Foster Will Chair the Audit Committee

High number of new directors

First quarter 2022 earnings released: EPS: CA$0.026 (vs CA$0.007 in 1Q 2021)

Insufficient new directors

Ceapro Inc. Announces Appointment of Geneviève Foster to Board of Directors

Full year 2021 earnings released: EPS: CA$0.037 (vs CA$0.024 in FY 2020)

Ceapro Inc., Annual General Meeting, Jun 01, 2022

Ceapro Appoints Ronnie Miller to its Board of Directors

Ceapro Appoints Ronnie Miller to its Board of Directors

Ceapro (CVE:CZO) Will Want To Turn Around Its Return Trends

Third quarter 2021 earnings released: EPS CA$0.011 (vs CA$0.002 in 3Q 2020)

Second quarter 2021 earnings released

Be Wary Of Ceapro (CVE:CZO) And Its Returns On Capital

Ceapro Inc. Announces Completion of Patient Enrollment in Clinical Study Evaluating Beta Glucan as A Cholesterol-Lowering Agent

Ceapro's (CVE:CZO) Robust Earnings Are Supported By Other Strong Factors

First quarter 2021 earnings released

Estimating The Fair Value Of Ceapro Inc. (CVE:CZO)

Full year 2020 earnings released

New 90-day low: CA$0.63

Will Ceapro (CVE:CZO) Multiply In Value Going Forward?

Is It Too Late To Consider Buying Ceapro Inc. (CVE:CZO)?

New 90-day high: CA$0.79

Estimating The Fair Value Of Ceapro Inc. (CVE:CZO)

Ceapro Inc. (CVE:CZO) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?

New 90-day high - CA$0.84

재무 상태 분석

부채 대 자본 내역 및 분석

대차 대조표

건강한 기업 발견하기